Gilead agrees 41,000 euro hep-C drug price for 12 week treatment

Drugmaker Gilead has agreed on a price for its hepatitis C drug Sovaldi of 41,000 euros ($46,625) for a 12-week treatment for Germany’s statutory medical insurers, the GKV association of Germany’s statutory medical insurers said. The drug had initially been offered in Germany for a list price of 60,000 euros, or about 56,500 euros including the discount.
Go to Source